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Abstract. Due to the fact that the number of new poorly soluble active pharmaceutical ingredients is
increasing, it is important to investigate the possibilities of improvement of their solubility in order to
obtain a final pharmaceutical formulation with enhanced bioavailability. One of the strategies to increase
drug solubility is the inclusion of the APIs in cyclodextrins. The aim of this study was to investigate the
possibility of aripiprazole solubility improvement by inclusion in (2-hydroxy)propyl-β-cyclodextrin
(HPBCD) and simultaneous manipulation of pH of the medium and addition of polyvinylpyrrolidone.
Aripiprazole–HPBCD complexes were prepared by spray drying aqueous drug–HPBCD solutions, and
their properties were compared with those prepared by solvent-drop co-grinding and physical mixing. The
obtained powders were characterized by thermoanalytical methods (TGA and DSC), FTIR spectroscopy,
their dissolution properties were assessed, while the binding of aripiprazole into the cavity of HPBCD was
studied by molecular docking simulations. The solubilization capacity was found to be dependent on pH as
well as the buffer solution’s ionic composition. The presence of PVP in the formulation could affect the
solubilization capacity significantly, but further experimentation is required before its effect is fully
understood. On the basis of solubility studies, the drug/HPBCD stoichiometry was found to be 1:3. The
spray-dried products were free of crystalline aripiprazole, they possessed higher solubility and dissolution
rate, and were stable enough over a prolonged period of storage. Spray drying of cyclodextrin solutions
proved to be an appropriate and efficient technique for the preparation of highly soluble inclusion
compounds of aripiprazole and HPBCD.
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INTRODUCTION
It is a well-established fact that the number of new poorly
soluble active pharmaceutical ingredients (APIs) is increasing
(1). Therefore, it is important to investigate the possibility of
improvement of their solubility in order to obtain a final
pharmaceutical formulation with enhanced bioavailability.
One of the strategies to increase drug solubility is the inclusion
of the APIs in cyclodextrins, which offers numerous additional
advantages, such as improvement of the formulation’s sta-
bility, safety, organoleptic properties, etc. (2). Due to these
advantages, there are many examples of drugs formulated
as cyclodextrin complexes on the market, such as piroxicam,
nimesulide, omeprazole, and itraconazole (3,4). Usually
desirable characteristics of a drug substance suitable for
complexation with cyclodextrin are: a skeleton of more
than five atoms (C, P, S, N) in the drug molecule, melting
point temperature of the substance below 250 °C, solubility
in water less than 10 mg/mL, molecular structure with less
than five condensed rings, and molecular weight between
100 and 400 (5). Even when the drug possesses all the
aforementioned favorable properties, in certain cases, further
enhancement of the solubilizing power of cyclodextrins is
desirable in order to reduce their necessary amount in a
drug formulation for several reasons including toxicity,
cost, and dosage, and it can be achieved by the selection
of an appropriate cyclodextrin type, pH adjustment of the
medium, and addition of different additives such as water-
soluble polymers in the formulation (4,6).
A typical example of an API whose solubility has been
enhanced by complexation with cyclodextrins is aripiprazole,
a novel API with antipsychotic action, available on the market
in the form of tablets, orally disintegrating tablets, oral syrup,
and injectable solution. Since it is practically insoluble in
water, formulation of dosage forms containing aripiprazole
suitable for oral and parenteral administration is an appealing
solution to its low bioavailability. Aripiprazole’s potential to
be a good drug candidate for complexation with cyclodextrins
has been recognized, and there is already a product containing
an aripiprazole-beta-cyclodextrin derivative complex, marketed
by Otsuka Pharmaceutical Company (Tokyo, Japan) under the
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brand name Abilify® in the form of intramuscularly injectable
solution. However, due to its high molecular weight (448.4),
incorporation in cyclodextrins is a challenging task and has not
been thoroughly investigated yet. Therefore, the present study
aims to elucidate the potential of further enhancing the solubil-
ity of aripiprazole using (2-hydroxy)propyl-β-cyclodextrin
(HPBCD), which is known for its good aqueous solubility
and low toxicity (3), and suitable manipulation of factors
that influence the drug–cyclodextrin interaction, such as
the pH of the medium and addition of polyvinylpyrrolidone
(PVP). Aripiprazole–cyclodextrin complexes were prepared
by spray drying aqueous solubilized drug solutions, and
their properties were compared with those prepared by
solvent-drop co-grinding and physical mixing. The obtained
powders were characterized by thermoanalytical methods
such as thermogravimetric analysis (TGA) and differential
scanning calorimetry (DSC), Fourier transform infrared
(FTIR) spectroscopy, and their dissolution properties were
assessed in order to evaluate the extent of drug solubility
and dissolution rate enhancement.
MATERIALS AND METHODS
Materials
In this study, the following materials were used: aripiprazole
(Neuland Laboratories, India); (2-hydroxy)propyl-β-cyclodextrin,
DS~5.6 (Kleptose HP, Roquette, France); Polyvinylpyrrolidone




Cyclodextrins are known to form hydrates; therefore,
they are likely to contain certain amounts of water depending
on hydration state, and for the preparation of aqueous
solutions of predefined molar concentration, this should
be considered for measurement of the appropriate amounts
of HPBCD. For the initial characterization of cyclodextrin
to be used in the study, semi-micro determination of water
was conducted by Karl Fischer titrimetry, which is based
upon the quantitative reaction of water with sulfur dioxide
and iodine in a suitable anhydrous medium in the presence
of a base with sufficient buffering capacity (Ph. Eur. 2.5.12
Method A), by using the Karl Fischer titrator (835 Titrando,
Metrohm, Switzerland).
For comparison purposes, loss on drying was also
determined for cyclodextrin by a gravimetric method for
samples of 2.5 g, using a Halogen moisture analyzer (Mettler-
Toledo HR 83, Greifensee, Switzerland) at a temperature of
105 °C, and measurement time until the mean weight loss drops
below 1 mg per 50 s.
Differential Scanning Calorimetry
DSC measurements of powder samples were carried out
using a Shimadzu DSC50 Differential Scanning Calorimeter
(Shimadzu Corporation, Tokyo, Japan). The thermal behavior
was studied by heating the samples (2–5 mg) in a sealed
aluminum pan from 30 to 300 °C, at a rate of 10 °C/min, using
nitrogen as purge gas (flow rate 25 cm3/min). An empty pan
was used as a reference.
Thermogravimetric Analysis
TGA measurements of powder samples were carried out
using a Shimadzu TGA50 Thermogravimetric Analyzer
(Shimadzu Corporation, Tokyo, Japan). The weight loss
was monitored during heating the samples (2–5 mg) in an
aluminum pan from 30 to 120 °C, at a rate of 10 °C/min,
and under a nitrogen flow of 25 cm3/min.
Fourier Transform Infrared Spectroscopy
Attenuated total reflectance (ATR) FTIR spectra
were obtained on a Shimadzu IR Prestige 21 spectrometer
(Shimadzu Europa GmbH, Duisburg, Germany), with a
horizontal Golden Gate MkII single-reflection ATR system
(Specac, Kent, UK) equipped with a heated diamond top
plate, ZnSe lenses and a 4000 series temperature controller.
Spectra were recorded between 4,000 and 500 cm−1 at a
resolution of 4 cm−1. A number of 32 scans were added for
each spectrum.
Phase Solubility Studies
The solubility of aripiprazole in the presence of cyclo-
dextrin was determined in different aqueous solution media
in order to elucidate the effect of pH and ionic composition.
Specifically, excess amounts of aripiprazole were added in
distilled water, and two different buffers, both of pH=3.0, a citrate
(Ph. Eur. 4008000) and a phosphate buffer (Ph. Eur. 4010000),
with increasing concentrations of HPBCD (0–320 mM). Suspen-
sions were stirred on a magnetic stirrer at room temperature for
48 h. All suspensions were filtered through a 0.45-μmmembrane
filter, suitably diluted and analyzed spectrophotometrically at
217.5 nm on a Camspec M330 UV spectrophotometer (Camspec
Inc., Cambridge, UK).
Preparation of Solid Systems
Solid drug–cyclodextrin systems were prepared by
spray drying the final clear solution obtained after filtration
of suspension from the phase solubility studies, on a Büchi
B-191 mini spray drier (Büchi Laboratoriums-Technik AG,
Flawil, Switzerland) under the following conditions: inlet
temperature 120 °C, outlet temperature 70 °C, pump set to
15 %, aspirator 100 %, and atomization 550 l/h.
Powder samples were also prepared by solvent-drop
co-grinding technique, with a cyclodextrin (CD)/drug molar
ratio of 16:1 (as obtained in phase solubility studies in pure
aqueous solutions of HPBCD). Cyclodextrin was wetted
with few droplets of methanol in a ceramic mortar. The
required amount of aripiprazole was then slowly added,
and the powders were mixed with ceramic pestle for about
15 min. During this process, an appropriate quantity of
methanol was added in order to maintain a suitable con-
sistency of mixture. The final product was then dried in an
oven at 40 °C for about 2 h and then allowed to equilibrate
at room temperature for 24 h.
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Two different physical mixtures, a mixture consisting of
aripiprazole and cyclodextrin, and another consisting of aripi-
prazole, cyclodextrin, and PVP, were prepared by blending
the powders in a PE bag simulating the mixing in the container
mixer, and used as reference.
Dissolution Study
Dissolution studies were conducted in Dissolution Tester
DT800 (Erweka, Heusenstamm, Germany) at 37±0.5 °C, in a
900-ml pH 1.2 medium (hydrochloric acid), using a USP
Apparatus II (paddle), at two different agitation rates: (a)
60 rpm [www.fda.gov (Dissolution method database)] and (b)
50 rpm (standard agitation speed,more discriminating condition).
For these studies, the solid formulations (pure drug, spray-dried
complex with HPBCD, and physical mixture with HPBCD) were
filled into hard gelatin capsules (size #0). Fill weight of each
capsule corresponded to approximately 10–11 mg of drug.
At the preset time intervals, aliquots were withdrawn from
the dissolution medium, filtered through a 0.45-μm membrane
filter, transferred to the spectrophotometer (8453 UV–visible
spectrophotometer, Agilent, Santa Clara, USA), and assayed
for aripiprazole at 250 nm. The test was repeated three times,
andmean values and relative standard deviationwere calculated.
Molecular Docking Simulations
Docking simulations were performed using the Auto-
Dock Vina software program that uses a sophisticated gradi-
ent local optimization algorithm, and automates grid map
generation and result clustering procedures (7). The starting
coordinates of aripiprazole were taken from the crystal struc-
ture of the commercial form A (CSD Ref No 285534),
CHARMm force field parameters (8) and Gasteiger charges
were assigned to the ligand atoms using the VEGA ZZ mo-
lecular modeling software (9), and energy minimization of
aripiprazole molecule was performed using the NAMD mo-
lecular dynamics suite (10). Subsequently, non-polar hydrogen
atoms were merged, and rotatable bonds were defined. Since
it is impractical to simulate all possible isomers of substituted
cyclodextrins, two representative isomers of (2-hydroxy)propyl-
β-cyclodextrin were chosen for the simulation on the basis of the
declared molecular substitution (M.S.) of the commercial prod-
uct (Kleptose HP, with M.S. of 0.99; Fig. 1): isomer (a), with
seven (2-hydroxy)propyl substituents placed on the O6 oxygens
since this is the most reactive site (11), and a randomly substitut-
ed isomer (b), with four (2-hydroxy)propyl substituents placed
on the O6 oxygens, and three on the next most reactive site, the
O2 oxygens (11). Non-polar hydrogen atoms were merged, Koll-
man united atom type charges, and solvation parameters were




The initial water content of the cyclodextrins, determined
by the two different methods, was very similar (expressed as the
mean of three determinations): by the Karl Fischer method,
water content was found to be 4.38 % (standard deviation,
0.15 %), and by loss on drying (gravimetric method), it was
found to be 4.27 % (standard deviation, 0.14 %). Results
obtained by Karl Fischer method were considered in the
calculation of appropriate amounts of HPBCD.
Thermal Analysis
From the differential scanning calorimetry thermograms
(Fig. 2), it is seen that aripiprazole has a melting endotherm in
the range of 138–150 °C with a maximum at 141 °C, indicating
that the raw material belongs to the crystalline form III (13),
with a small secondary melting endotherm at 150 °C that
can be attributed to the existence of a very small amount
of form I.
The absence of a melting endotherm of the drug in the
spray-dried product indicates that the total aripiprazole
amount is included in the cavity of the cyclodextrins in a
Fig. 1. (2-Hydroxy)propyl-β-cyclodextrin isomers used for the docking simulations: isomer a, with substitution only at the O6 position, and isomer
b, having substituents at the O6 and O2 positions
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non-crystalline state (Fig. 2c). In the physical mixture, howev-
er (Fig. 2d), the melting endotherm of aripiprazole is still
present, confirming the existence of crystalline drug and there-
fore the inability to form an inclusion compound by physical
mixing. Another interesting feature of the thermograms is the
broad endotherm spanning from room temperature to 100 °C,
with a maximum in the range of 79–80 °C that probably
corresponds to the loss of strongly bound water from the
cyclodextrin hydration shell. No effect of the cyclodextrin
molar concentration in the spray drying solution was observed
in the thermograms, indicating that the amounts of cyclodex-
trins used in the present study were suitable and sufficient to
fully include the drug in a molecular state.
Samples prepared by solvent-drop co-grinding of aripipra-
zole with cyclodextrin used in this study (Fig. 2e) exhibit a small
melting endotherm at 141 °C, indicating the presence of a small
amount of crystalline aripiprazole that has not been included
in the cavity of the cyclodextrin. Although the solvent-drop
co-grinding method appears as an attractive solvent and
energy-saving alternative, more experimental work is required
for the optimization of its parameters, which is beyond the scope
of the present study.
Thermogravimetric analysis of the samples shows the
following mass loss: 6.0 w/w, 5.9 w/w, and 5.5 % w/w for
the HPBCD, aripiprazole–HPBCD spray-dried complex,
and aripiprazole–HPBCD physical mixture, respectively
(standard deviation, <1.5 %). The mass loss is occurring
almost from room temperature and until ~90 °C, which
supports the view that there is loss of bound water in this
temperature range. The mass loss observed in the thermo-
grams is very close to the water content determined by
Karl Fischer titrimetry, with the spray-dried products show-
ing a slight increase in water content, probably resulting
from further hydration of the cyclodextrins in solution. The
water of hydration is strongly bound, and it cannot be
removed, despite the high temperature applied during the
spray drying process.
FTIR Spectroscopy
Figure 3 illustrates ATR-FTIR spectra of aripiprazole,
cyclodextrin, spray-dried product, and corresponding physical
mixture. Aripiprazole (Fig. 3a) shows characteristic reflec-
tance bands of polymorph III (13), in agreement with the
melting range observed in the DSC thermograms. Specifically,
the NH stretching vibration appears at 3,190 cm−1, CH2
stretching is seen at 2,945 cm−1, while the carbonyl stretching
vibration is located at 1,684 cm−1, and the O–Ar bond stretch
shows multiple peaks at 1,291, 1,275, and 1,239 cm−1.
The FTIR spectrum of pure cyclodextrin treated by
spray drying without the presence of drug in the solution
(Fig. 3b) shows a broad reflectance band in the range of
3,100–3,600 cm−1 with a maximum of ~3,340 cm−1, which is
attributed to the OH stretching vibrations, indicating a
strong association of the hydroxyl groups via hydrogen
bonds. However, the existence of lower intensity but
sharp peaks in the range of 3,600–3,700 cm−1 indicates
the presence of free OH groups that possibly belong to
adsorbed water that is not fully involved in hydrogen
bonds.
Regarding the inclusion complex prepared by spray
drying (Fig. 3c), the drug can be identified in the CH,
CO, and in the fingerprint region; however, the intensity
of aripiprazole’s peaks in the inclusion compounds is rather
low, in contrast to the spectra of physical mixtures
(Fig. 3d), where the drug shows clearly higher intensity
peaks, indicating weaker or no interaction between the
drug and the cyclodextrin when physically mixed.
Molecular Docking Simulations
Molecular docking simulations showed that aripiprazole
can form stable complexes acquiring various conformations.
Figure 4a, b illustrates representative complexes of aripiprazole
with HPBCD isomer (a), while Fig. 4c, d illustrates representa-
tive complexes of aripiprazole with HPBCD isomer (b) (apolar
Fig. 2. Representative DSC thermograms of aripiprazole a, HPBCD b,
aripiprazole–HPBCD inclusion compound produced by spray drying at
160 mMHPBCD concentration c, physical mixture of aripiprazole with
HPBCD d, and aripiprazole–HPBCD inclusion compound produced by
solvent-drop co-grinding e
Fig. 3. Representative ATR-FTIR spectra of aripiprazole a, HPBCD
b, aripiprazole–HPBCD inclusion compound produced by spray dry-
ing at 160 mM HPBCD concentration c, and corresponding physical
mixture of aripiprazole with HPBCD d
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hydrogens have been removed for clarity). The most stable
complex is formed when aripiprazole acquires a bent conforma-
tion (Fig. 4a), although it is possible to form complexes having a
linear conformation (Fig. 4b). The highest estimated binding
affinity is equal to −7.6 kcal/mol and corresponds to a complex
with HPBCD isomer (a) (Fig. 4a). The existence of a hydrogen
bond between the N–H hydrogen of aripiprazole and a neighbor-
ing O–H oxygen of HPBCD with an energy of −0.54 kcal/mol
(calculated using CHARMm force field parameters) indicates the
importance of hydrogen bonding interactions in the stabilization
of the complexes. The estimated binding affinities for complexes
in which aripiprazole has a linear conformation (Fig. 4b) are
generally lower.
The location of the (2-hydroxy)propyl substituents also
seems to affect binding. The highest calculated binding affinity
for isomer (b) that has some (2-hydroxy)propyl substituents
randomly placed in the O2 primary hydroxyl groups (Fig. 4c, d)
was −6.4 kcal/mol, and the energy of the hydrogen bond
between the aripiprazole N–H and a neighboring hydroxyl
group of HPBCD was calculated to be −0.36 kcal/mol. Weaker
binding of aripiprazole in HPBCD isomer (b) can be attributed
to steric hindrance and prevention of approach into the
hydrophobic cavity. Considering that the commercial products
are usually mixtures of isomers consisting mainly of O6-
substituted HPBCD (isomer (a), Fig. 1), with some amount
of the O2- and O3-substituted HPBCD, the different binding
affinities could further complicate the interpretation of the
results of phase solubility studies.
Phase Solubility Studies
Effects of pH, Ionic Composition, and Addition of PVP
Τhe amount of cyclodextrin needed to achieve maximum
drug solubility can be determined by phase solubility studies.
Aripiprazole is a drug with basic character, and it shows a
pH-dependent solubility that decreases with increasing pH.
Therefore, in order to elucidate the effect of the pH and
ionic composition of the dissolution medium on the solubility of
aripiprazole in the presence of HPBCD, the following media
were employed in the phase solubility studies: pure (distilled)
water, pH 3.0 citrate buffer solution, and pH 3.0 phosphate
buffer solution. Additionally, the potential for further solubility
improvement by addition of small amounts of PVP was also
studied since it is known that PVP could have some influence on
the solubilizing effect ofHPBCD (14). Besides, PVP is known to
act as a nucleation inhibitor (3,15), so it might contribute to the
stability of the samples. The results are summarized in Fig. 5 and
Tables I and II.
It is seen that while the solubility in pure aqueous
solutions of CD is low, a significant improvement can be
achieved in citrate buffer pH 3 (Table I). Li et al. (16)
described the importance of the combined effects of pH
and complexation on solubility and the importance of the
ionized species in contributing the overall complexation of
drugs. It is often assumed that the unionized species are
primarily responsible for the formation of the complex and
Fig. 4. Representative docked conformations of aripiprazole in different HPBCD isomers
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the subsequent increase in solubility. However, ionization
of a drug can also result in enhanced complexation, and
the solubility of the ionized drug complex can sometimes
exceed the solubility of the unionized drug complex.
It can also be observed that the solubility of aripiprazole
is dependent not only on the pH of the medium but also on the
type of buffer present. Comparing the drug solubility in pH 3.0
phosphate buffer (inorganic salt) and pH 3.0 citrate buffer
(hydroxycarboxylic acid), in the absence of HPBCD there is
no big difference in drug solubility. However, in the presence
of HPBCD, choice of buffer has a significant effect on the drug
solubility. This phenomenon was also described by Buchanan
et al. (17) for the antifungal drugs and HPBCD. By observing
the St/So ratio (St representing the drug solubility in the pres-
ence of HPBCD and So intrinsic solubility in the same medium
without HPBCD), the calculated value for pure aqueous me-
dium is ca 167.6, in phosphate buffer ca 6.5, and in citrate
buffer ca 95.1 It is clear that cyclodextrin plays an important
role in the solubilization of the aripiprazole, together with the
ionic composition of the buffer, rather than the pH itself. The
solubility of the corresponding complexes can be much higher
than what could be expected by increasing the total drug
solubility through only appropriate pH adjustment. This is
possibly due to the specific interaction of the hydroxy acid
groups with the hydrogen bond system of the host and/or the
modification of the hydrogen bonding network of the sur-
rounding water molecules (6). The drugs can be strongly
bound inside the CD cavity even though they are in the
ionized form because their basic center (and hence the charge)
can be located quite far away from the molecule’s hydropho-
bic part that is included in the CD cavity, so the complexation
ability is not significantly compromised. Moreover, the hy-
droxy acid can interact with the external hydrogen bonding
system of CDs by a mechanism that involves the binding of the
hydrophobic part of the drug and simultaneous formation of a
strong ion pair. Redenti et al. (6) indicated a number of
requirements for exploiting the properties of the multi-com-
ponent complexation technology, among which are drug solu-
bility less than 0.1 mg/mL, presence of an amino group with a
fairly basic character (pKa>5.0), etc.
Regarding the effect of PVP, it is seen in Fig. 5 that
addition of PVP (mass ratio of PVP/CD 0.005) causes a de-
crease of solubility, which is in agreement with previous stud-
ies (18), and it can be attributed to the competition of polymer
and drug for complexation with CD. However, optimizing the
concentration of PVP could contribute to solubility improve-
ment, as suggested by solubility results obtained CD solutions
of the same concentration but with different concentration of
PVP (different PVP/CD mass ratio; Table II).
Based on results obtained in phase solubility studies, it
could be concluded that the improvement of aripiprazole’s
solubility was most significant in citrate buffer with pH 3.0.
In this medium, complexation of aripiprazole by HPBCD was
the most efficient at the 160-mM CD concentration, as shown
by the smallest CD/dissolved drug mass ratio obtained.
Analysis of Solubility Curves
In general, based on the shape of the generated phase
solubility relationships, several types of behaviors can be
identified (19). From the shapes of the dissolution curves
obtained in different media (Fig. 5), and taking into account
the variety of conformations that aripiprazole can assume to
form complexes with HPBCD of varying stability, as suggested
by docking simulations, it can be assumed that there are
complex mechanisms involved in aripiprazole solubilization.
In this study, aripiprazole solubility was examined in a wider
range of cyclodextrin concentration, and depending on con-
centration range observed, several different A profiles can be
recognized. In so-called A systems, the apparent solubility of
the substrate increases as a function of CD concentration.
Fig. 5. Phase solubility diagrams for aripiprazole and HPBCD in
different media
Table I. Aripiprazole Solubility Results that Show the Influence of
pH and Ionic Composition of the Medium on Drug Solubility, With





Citrate buffer pH 3 1.576
Phosphate buffer pH 3 2.420
160 mM HPBCD solution in pure water 1.508
160 mM HPBCD solution in citrate buffer pH 3 149.884
160 mM HPBCD solution in phosphate buffer pH 3 15.687
Table II. Aripiprazole Solubility Results that Show the Influence of






Citrate buffer pH 3 1.576
Citrate buffer pH 3, 0.2% w/w PVP 0.934
260 mM HPBCD solution in pure water 9.729
260 mM HPBCD solution in pure water, PVP/CD 0.005a 10.961
260 mM HPBCD solution in pure water, PVP/CD 0.0025b 7.788
260 mM HPBCD solution in citrate buffer pH 3 172.502
260 mMHPBCD solution in citrate buffer pH 3, PVP/CD 0.005a 155.032
260 mMHPBCD solution in citrate buffer pH 3, PVP/CD 0.0025b 184.317
a PVP concentration 0.2 % w/w
b PVP concentration 0.1 % w/w
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In an aqueous medium containing only aripiprazole and
HPBCD, an AP type curve could be observed, suggesting
formation of higher-order complexes at higher CD concentration
(Fig. 6). As the stoichiometry of the system can be probed by
curve fitting of the diagram with linear, quadratic, or a cubic
model, for this isotherm the cubic function showed the best fit
(R2=0.996), suggesting a 1:3 complex formation (D(CD)3).
Phase solubility diagrams in citrate buffer medium with
and without addition of PVP (Fig. 7) showed profiles that can
be classified as AN subtype because at the higher CD concen-
trations a negative deviation from linearity exists, meaning
that CD is less effective at higher concentrations. Best fit
was obtained for a cubic function (R2=0.996 with PVP, R2=
0.987 without PVP) suggesting the formation of a 1:3 complex
(D(CD)3).
Similar curvature shapes of the phase solubility profiles
were reported by Buchanan et al. (17) for the antifungal drugs
and HPBCD in some buffers. AN profiles were explained by
bulk changes imparted to the solvent by the solubilizer at
various concentrations and/or self-association of the solubil-
izer (HPBCD) at high concentrations.
Solubility profile could be characterized as a normal pro-
file with a negative deviation at low CD concentrations (AL
−),
with y-intercept at the negative part of the axis. This behavior
was reported by Loftsson et al. (19) and explained by self-
association of poorly soluble drug molecules and drug/
cyclodextrin complexes, non-inclusion complexation, and
excipient interactions. It is possible that the observed
solubility increase is a cooperative effect of several different
solubilizing processes and interactions. The various anomalies
observed in the solubility curves, such as the significant
deviation of the experimental intrinsic solubility from that
estimated from the y-intercept, or even the negative solubility
Fig. 6. Phase solubility diagram for aripiprazole in HPBCD solution
in water
Fig. 7. Phase solubility diagrams for media with the most significant solubility improvement: a citrate buffer pH 3; b citrate buffer pH 3 with PVP
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value suggest the possibility of formation of multi-component
complexes and simultaneous formation of inclusion and
non-inclusion complexes, or self-association phenomena
(3,19,20).
Long-Term Stability of Aripiprazole–Cyclodextrin Inclusion
Compounds
The long-term stability of aripiprazole–cyclodextrin in-
clusion compounds upon storage in ambient conditions was
examined after 6 and 12 months by differential scanning cal-
orimetry and thermogravimetric analysis (results not shown).
No sign of aripiprazole crystallization could be identified in
the thermograms (complete absence of endotherm peaks
corresponding to the melting of aripiprazole), which suggests
that the inclusion compounds are stable, and no spontaneous
crystallization of the dug occurs over a prolonged period of
storage. Additionally, examination of the water content by
TGA showed no significant change, further supporting the
view that the cyclodextrin complexes are stable.
Dissolution Study
For the assessment of drug dissolution rate improvement,
dissolution studies were conducted. Figure 8 shows the percent
of aripiprazole dissolved vs time for an aripiprazole–HPBCD
complex, in comparison to the corresponding physical mixture
and pure aripiprazole, at different agitation rates. It is seen that
more than 80% of aripiprazole was dissolved from the complex
with HPBCD already after 10 min regardless of agitation rate,
which was not the case for the other samples. The presence of
cyclodextrin in physical mixture with aripiprazole also contrib-
uted to some dissolution improvement in vitro. However, by
observing the relative standard deviation values (represented
by error bars on Fig. 8), it was concluded that only from the
spray-dried drug–CD complex was the dissolution very rapid
and uniform, which is a significant characteristic of the dissolu-
tion profile. Therefore, the results obtained in this study suggest
that the complexation of aripiprazole with cyclodextrins could
be used as a formulation strategy for solubility and dissolution
rate enhancement.
Having in mind pH-dependent aripiprazole solubility, it
would be interesting to further examine the dissolution of
aripiprazole from complexes with HPBCD in dissolution media
with different pH. As it was reported in a study by Nacsa et al.
(21), there is a possibility that the solubility of a drug can
become independent of the pH through the application of CD
for drug complexation. Since the difference between the profiles
was more pronounced at the lower agitation speed, which was
expected, this dissolution condition should be used for future
dissolution studies, as being more discriminative.
CONCLUSIONS
Spray drying of cyclodextrin solutions proved to be an
efficient technique for the preparation of highly soluble inclu-
sion compounds of aripiprazole and HPBCD. The spray-dried
products were free of crystalline aripiprazole, they possessed
higher solubility and dissolution rate, and proved to be stable
enough over a prolonged period of storage.
The solubilization capacity was found to be dependent on
pH as well as the buffer solution’s ionic composition, with
maximum solubilization being achieved in citrate buffer with
a pH value of 3. On the basis of solubility studies, the drug/
cyclodextrin stoichiometry was found to be 1:3.
The presence of PVP in the spray drying solution can affect
the solubilization capacity significantly, but further experimen-
tation is required before its effect is fully understood.
Docking simulations confirmed aripiprazole’s ability to
form stable inclusion complexes with HPBCD and also
suggested complicated interactions owing to the flexibility
of the drug’s backbone.
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